References
- Garcia RodriguezLAGozalez-PerezAJohanssonSRisks factors for inflammatory bowel disease in the general populationAliment Pharmacol Ther20052230931516097997
- EkbomAThe changing faces of Crohn’s disease and ulcerative colitisTarganSRShanahanFKarpLCInflammatory Bowel Disease. From Bench to BedsideNew York, NYSpringer Science2003520
- RanziTBodiniPZambelliAEpidemiological aspects of inflammatory bowel disease in a north Italian population: A 4-year prospective studyEur J Gastroenterol Hepatol199686576618853254
- HowarthGFRobinsonMHEJenkinsDHigh prevalence of undetected ulcerative colitis: Data fom the Nottingham Fecal Occult Blood Screening TrialAm J Gastroenterol20029769069411926210
- http://www.amiciitalia.net/index.php?option=com_docman&task=doc-download&gid=131
- RubinGPHunginAPSKellyPJLingJInflammatory bowel disease: Epidemiology and management in an English general practice populationAliment Pharmacol Ther2000141553155911121902
- NumansMEChronic abdominal painJonesRBrittenNCulpepperLGassDGrolRMantD SilagyOxford Textbook of Primary Medical CareOxfordOxford University Press2005742746
- SandsBECrohn’s diseaseFeldmanMFriedmanLSBrandtLJSleisenger and Fordtran’s Gastrointestinal and Liver DiseasePhiladelphia, PASaunders Elsevier200624592498
- RollandNGrandbastienBMerleVCoùt de la première prise en charge des maladies inflammatoires chronique de l’intestinGastroenterol Clin Biol199923483488 French10416112
- StoneMAMayberryJFBakerRPrevalence and management of inflammatory bowel disease: A cross-sectional study from central EnglandEur J Gastroenterol Hepatol2003151275128014624149
- KonikoffMRDensonLARole of the calprotectin as a biomarker of intestinal inflammation in inflammatory bowel diseaseInflamm Bowel Dis20061252453416775498
- D’IncàRDal PontEDi LeoVCan calprotectin predict relapse risk in inflammatory bowel disease?Am J Gastroenterol20081032007201418802997
- WilliamsJGCheungWYRusselITOpen access follow up for inflammatory bowel disease: Pragmatic randomised trial and cost effectiveness studyBr Med J200032054454810688560
- CasellasFFontanetGBorruelNThe opinion of patients with inflammatory bowel disease on healthcare receivedRev Esp Enferm Dig20049617418415053732
- DrossmannDARingelYPsychosocial factors in ulcerative colitis and Crohn’s diseaseSartorRBSandbornWJKirsner’s Inflammatory Bowel DiseasesEdinburghSaunders2004340356
- MartinatoMFerranteMBurattinBUnderstanding of disease in patients with a recent diagnosis of inflammatory bowel diseaseJournal of Crohn’s and Colitis Suppl2008245
- de BoerAGSprangersMABarrtelsmanJFPredictors of health care utilization in patients with inflammatory bowel disease: A longitudinal studyEur J Gastroenterol Hepatol1998107837899831274
- D’IncàRBertomoroPMazzoccoKVettoratoMGRumiatiRSturnioloGCRisk factors for non-adherence to medication in inflammatory bowel disease patientsAliment Pharmacol Ther20082716617217949472
- CunliffeRNScottBBReview article: Monitoring for drug side-effects in inflammatory bowel diseaseAliment Pharmacol Ther20021664766211929382
- SossaiPCappellatoMGStefaniSCan a drug-induced hypersensitivity reaction be dose-dependent? A case with mesalamineMt Sinai J Med20016838939511687867
- StarkRKonigHHLeidlRCosts of inflammatory bowel disease in GermanyPharmacoeconomics20062479781416898849
- CornishJTanETeareJA meta-analysis on the influence of inflammatory bowel disease on pregnancyGut20075683083717185356